A BILL 
To amend the 21st Century Cures Act to provide for designa-
tion of institutions of higher education that provide re-
search, data, and leadership on continuous manufac-
turing as National Centers of Excellence in Continuous 
Pharmaceutical Manufacturing, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘National Centers of 
4
Excellence in Continuous Pharmaceutical Manufacturing 
5
Act of 2021’’. 
6
22:44 Jul 19, 2021
H4369
2 
•HR 4369 IH
SEC. 2. NATIONAL CENTERS OF EXCELLENCE IN CONTIN-
1
UOUS PHARMACEUTICAL MANUFACTURING. 
2
(a) IN GENERAL.—Section 3016 of the 21st Century 
3
Cures Act (21 U.S.C. 399h) is amended to read as follows: 
4
‘‘SEC. 3016. NATIONAL CENTERS OF EXCELLENCE IN CON-
5
TINUOUS 
PHARMACEUTICAL 
MANUFAC-
6
TURING. 
7
‘‘(a) IN GENERAL.—The Secretary of Health and 
8
Human Services, acting through the Commissioner of 
9
Food and Drugs— 
10
‘‘(1) shall solicit and, beginning not later than 
11
one year after the date of enactment of the National 
12
Centers of Excellence in Continuous Pharmaceutical 
13
Manufacturing Act of 2021, receive requests from 
14
institutions of higher education to be designated as 
15
a National Center of Excellence in Continuous Phar-
16
maceutical Manufacturing (in this section referred to 
17
as a ‘National Center of Excellence’) to support the 
18
advancement and development of continuous manu-
19
facturing; and 
20
‘‘(2) shall so designate any institution of higher 
21
education that— 
22
‘‘(A) requests such designation; and 
23
‘‘(B) meets the criteria specified in sub-
24
section (c). 
25
22:44 Jul 19, 2021
H4369
3 
•HR 4369 IH
‘‘(b) REQUEST FOR DESIGNATION.—A request for 
1
designation under subsection (a) shall be made to the Sec-
2
retary at such time, in such manner, and containing such 
3
information as the Secretary may require. Any such re-
4
quest shall include a description of how the institution of 
5
higher education meets or plans to meet each of the cri-
6
teria specified in subsection (c). 
7
‘‘(c) CRITERIA FOR DESIGNATION DESCRIBED.—The 
8
criteria specified in this subsection with respect to an in-
9
stitution of higher education are that the institution has, 
10
as of the date of the submission of a request under sub-
11
section (a) by such institution— 
12
‘‘(1) physical and technical capacity for re-
13
search and development of continuous manufac-
14
turing; 
15
‘‘(2) manufacturing knowledge-sharing net-
16
works with other institutions of higher education, 
17
large and small pharmaceutical manufacturers, ge-
18
neric and nonprescription manufacturers, contract 
19
manufacturers, and other entities; 
20
‘‘(3) proven capacity to design and demonstrate 
21
new, highly effective technology for use in contin-
22
uous manufacturing; 
23
22:44 Jul 19, 2021
H4369
4 
•HR 4369 IH
‘‘(4) a track record for creating and transfer-
1
ring knowledge with respect to continuous manufac-
2
turing; 
3
‘‘(5) the potential to train a future workforce 
4
for research on and implementation of advanced 
5
manufacturing and continuous manufacturing; and 
6
‘‘(6) experience in participating in and leading 
7
a continuous manufacturing technology partnership 
8
with other institutions of higher education, large and 
9
small pharmaceutical manufacturers, generic and 
10
nonprescription manufacturers, contract manufac-
11
turers, and other entities— 
12
‘‘(A) to support companies with continuous 
13
manufacturing in the United States; 
14
‘‘(B) to support Federal agencies with 
15
technical assistance, which may include regu-
16
latory and quality metric guidance as applica-
17
ble, for advanced manufacturing and continuous 
18
manufacturing; 
19
‘‘(C) with respect to continuous manufac-
20
turing, to organize and conduct research and 
21
development activities needed to create new and 
22
more effective technology, capture and dissemi-
23
nate expertise, create intellectual property, and 
24
maintain technological leadership; 
25
22:44 Jul 19, 2021
H4369
5 
•HR 4369 IH
‘‘(D) to develop best practices for design-
1
ing continuous manufacturing; and 
2
‘‘(E) to assess and respond to the work-
3
force needs for continuous manufacturing, in-
4
cluding the development of training programs if 
5
needed. 
6
‘‘(d) TERMINATION
OF DESIGNATION.—The Sec-
7
retary may terminate the designation of any National Cen-
8
ter of Excellence designated under this section if the Sec-
9
retary determines such National Center of Excellence no 
10
longer meets the criteria specified in subsection (c). Not 
11
later than 60 days before the effective date of such a ter-
12
mination, the Secretary shall provide written notice to the 
13
National Center of Excellence, including the rationale for 
14
such termination. 
15
‘‘(e) CONDITIONS FOR DESIGNATION.—As a condi-
16
tion of designation as a National Center of Excellence 
17
under this section, the Secretary shall require that an in-
18
stitution of higher education enter into an agreement with 
19
the Secretary under which the institution agrees— 
20
‘‘(1) to collaborate directly with the Food and 
21
Drug Administration to publish the reports required 
22
by subsection (g); 
23
22:44 Jul 19, 2021
H4369
6 
•HR 4369 IH
‘‘(2) to share data with the Food and Drug Ad-
1
ministration regarding best practices and research 
2
generated through the funding under subsection (f); 
3
‘‘(3) to develop, along with industry partners 
4
(which may include large and small biopharma-
5
ceutical manufacturers, generic and nonprescription 
6
manufacturers, and contract manufacturers) and an-
7
other institution or institutions designated under 
8
this section, if any, a roadmap for developing a con-
9
tinuous manufacturing workforce; 
10
‘‘(4) to develop, along with industry partners 
11
and other institutions designated under this section, 
12
a roadmap for strengthening existing, and devel-
13
oping new, relationships with other institutions; and 
14
‘‘(5) to provide an annual report to the Food 
15
and Drug Administration regarding the institution’s 
16
activities under this section, including a description 
17
of how the institution continues to meet and make 
18
progress on the criteria listed in subsection (c). 
19
‘‘(f) FUNDING.— 
20
‘‘(1) IN GENERAL.—The Secretary shall award 
21
funding, through grants, contracts, or cooperative 
22
agreements, to the National Centers of Excellence 
23
designated under this section for the purpose of 
24
studying and recommending improvements to contin-
25
22:44 Jul 19, 2021
H4369
7 
•HR 4369 IH
uous manufacturing, including such improvements 
1
as may enable the Centers— 
2
‘‘(A) to continue to meet the conditions 
3
specified in subsection (e); and 
4
‘‘(B) to expand capacity for research on, 
5
and development of, continuing manufacturing. 
6
‘‘(2) CONSISTENCY WITH FDA MISSION.—As a 
7
condition on receipt of funding under this sub-
8
section, a National Center of Excellence shall agree 
9
to consider any input from the Secretary regarding 
10
the use of funding that would— 
11
‘‘(A) help to further the advancement of 
12
continuous manufacturing through the National 
13
Center of Excellence; and 
14
‘‘(B) be relevant to the mission of the 
15
Food and Drug Administration. 
16
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
17
There is authorized to be appropriated to carry out 
18
this subsection $80,000,000 for the period of fiscal 
19
years 2022 through 2026. 
20
‘‘(4) RULE
OF
CONSTRUCTION.—Nothing in 
21
this section shall be construed as precluding a Na-
22
tional Center for Excellence designated under this 
23
section from receiving funds under any other provi-
24
sion of this Act or any other Federal law. 
25
22:44 Jul 19, 2021
H4369
8 
•HR 4369 IH
‘‘(g) ANNUAL REVIEW AND REPORTS.— 
1
‘‘(1) ANNUAL
REPORT.—Beginning not later 
2
than one year after the date on which the first des-
3
ignation is made under subsection (a), and annually 
4
thereafter, the Secretary shall— 
5
‘‘(A) submit to Congress a report describ-
6
ing the activities, partnerships and collabora-
7
tions, Federal policy recommendations, previous 
8
and continuing funding, and findings of, and 
9
any other applicable information from, the Na-
10
tional Centers of Excellence designated under 
11
this section; and 
12
‘‘(B) make such report available to the 
13
public in an easily accessible electronic format 
14
on the website of the Food and Drug Adminis-
15
tration. 
16
‘‘(2) REVIEW OF NATIONAL CENTERS OF EX-
17
CELLENCE AND POTENTIAL DESIGNEES.—The Sec-
18
retary shall periodically review the National Centers 
19
of Excellence designated under this section to ensure 
20
that such National Centers of Excellence continue to 
21
meet the criteria for designation under this section. 
22
‘‘(3) REPORT ON LONG-TERM VISION OF FDA 
23
ROLE.—Not later than 2 years after the date on 
24
which the first designation is made under subsection 
25
22:44 Jul 19, 2021
H4369
9 
•HR 4369 IH
(a), the Secretary, in consultation with the National 
1
Centers of Excellence designated under this section, 
2
shall submit a report to the Congress on the long- 
3
term vision of the Department of Health and 
4
Human Services on the role of the Food and Drug 
5
Administration in supporting continuous manufac-
6
turing, including— 
7
‘‘(A) a national framework of principles re-
8
lated to the implementation and regulation of 
9
continuous manufacturing; 
10
‘‘(B) a plan for the development of Federal 
11
regulations and guidance for how advanced 
12
manufacturing and continuous manufacturing 
13
can be incorporated into the development of 
14
pharmaceuticals and regulatory responsibilities 
15
of the Food and Drug Administration; and 
16
‘‘(C) appropriate feedback solicited from 
17
the public, which may include other institutions, 
18
large and small biopharmaceutical manufactur-
19
ers, generic and nonprescription manufacturers, 
20
and contract manufacturers. 
21
‘‘(h) DEFINITIONS.—In this section: 
22
‘‘(1) ADVANCED MANUFACTURING.—The term 
23
‘advanced manufacturing’ means an approach for 
24
the manufacturing of pharmaceuticals that incor-
25
22:44 Jul 19, 2021
H4369
10 
•HR 4369 IH
porates novel technology, or uses an established 
1
technique or technology in a new or innovative way 
2
(such as continuous manufacturing where the input 
3
materials are continuously transformed within the 
4
process by two or more unit operations) that en-
5
hances drug quality or improves the manufacturing 
6
process. 
7
‘‘(2) 
CONTINUOUS
MANUFACTURING.—The 
8
term ‘continuous manufacturing’— 
9
‘‘(A) means a process where the input ma-
10
terials are continuously fed into and trans-
11
formed within the process, and the processed 
12
output materials are continuously removed from 
13
the system; and 
14
‘‘(B) consists of an integrated process that 
15
consists of a series of two or more unit oper-
16
ations. 
17
‘‘(3) INSTITUTION OF HIGHER EDUCATION.— 
18
The term ‘institution of higher education’ has the 
19
meaning given such term in section 101(a) of the 
20
Higher Education Act of 1965 (20 U.S.C. 1001(a)). 
21
‘‘(4) SECRETARY.—The term ‘Secretary’ means 
22
the Secretary of Health and Human Services, acting 
23
through the Commissioner of Food and Drugs.’’. 
24
22:44 Jul 19, 2021
H4369
11 
•HR 4369 IH
(b) TRANSITION RULE.—Section 3016 of the 21st 
1
Century Cures Act (21 U.S.C. 399h), as in effect on the 
2
day before the date of the enactment of this section, shall 
3
apply with respect to grants awarded under such section 
4
before such date of enactment. 
5
Æ 
22:44 Jul 19, 2021
H4369
